According to our latest study, “Medical Cyclotron Market Forecast to 2028 – COVID-19 Impact and Global Analysis – by Type, Capacity, and End User,” the Medical Cyclotron market size is projected to grow from US$ 202.34 million in 2022 to US$ 332.49 million by 2028; it is estimated to grow at a CAGR of 8.6% from 2022 to 2028.
General Electric Company; Best ABT Molecular Imaging, Inc.; IBA; Sumitomo Heavy Industries, Ltd.; Siemens AG; Advanced Cyclotron Systems; ISOSOLUTION; ALCEN; IONETIX Corporation; and Best Cyclotron System, Inc. are among the key players operating in the Medical Cyclotron market.
Get sample Copy Of This Report@ https://www.theinsightpartners.com/sample/TIPHE100001233/
Based on capacity, the medical cyclotron market is segmented into 10-12 MeV, 16-18 MeV, 19-24 MeV, and 24 MeV and above. The 16-18 MeV segment will hold the largest share of the market in 2022. The same segment is estimated to register the highest CAGR of 9.1% during the forecast period. The 16-18 MeV range is generally used for small medical cyclotrons, capable of producing considerable quantities of Technetium-99m (99mTc).
The report highlights the key factors driving the market and prominent players with their developments. The increasing prevalence of cancer and growing inclination toward nuclear scans for accurate diagnosis is driving the market growth. However, the high cost of procedures and lack of expertise are hindering the market’s growth.
For instance, GE Healthcare offers PETtrace 800 series cyclotrons that operate at 16.5 MeV protons and has maximum acceleration beam intensity of 130 μA. This range of energy is widely accepted as it offers maximum capacity and consistent yields. Due to its compact size, it utilizes small space and is installed easily and quickly. The 16-18 MeV range is generally used to produce an 18F-Fluoride radio particle. These are also accounted for as compact medical cyclotrons with self-shielding to reduce neutron fluxes. 18 MeV are unshielded cyclotrons, and 16.5-MeV are self-shielded cyclotrons.
The facts of this report are believed to be correct at the time of publication but cannot be guaranteed. Please note that the findings, conclusions, and recommendations that “The Insight Partners” delivers will be based on information gathered in good faith from primary and secondary sources, whose accuracy we are not always in a position to guarantee. As such, “The Insight Partners” can accept no liability whatsoever for actions taken based on any information that may subsequently prove to be incorrect.